A phase 3 study of ALLO 501A in earlier line LBCL
Latest Information Update: 13 Mar 2023
At a glance
- Drugs Cemacabtagene ansegedleucel (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 13 Mar 2023 New trial record
- 28 Feb 2023 According to a Allogene Therapeutics media release, the company plans to initiate this study in 1H 2024.